Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence.
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Xin
X
Gao
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Paul A
PA
VanderLaan
Dana-Farber Community Cancer Care, Weymouth, MA.
Alexandra S
AS
Bailey
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address: dbcosta@bidmc.harvard.edu.
Daniel B
DB
Costa
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D059014:High-Throughput Nucleotide Sequencing / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000235:genetics*; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000235:genetics*; D055752:Small Cell Lung Carcinoma / Q000175:diagnosis / Q000235:genetics*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents
Metachronous; Next-generation sequencing; Recurrent; Small cell lung cancer; TP53